Immortalizing MSCs for Continuous EV Harvesting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The scalability of mesenchymal stem cell (MSC)-derived extracellular vesicle (EV) production is limited by the finite lifespan of MSCs, which restricts the continuous harvesting of therapeutically active EVs for medical applications.
Innovation Solution
A method involving the immortalization of MSCs using human Telomerase reverse transcriptase (hTERT) protein and inhibitors of cell cycle regulators/tumor suppressor proteins, such as p21, p16, and p53, to create immortalized cell lines that can continuously secrete therapeutically active EVs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If MSCs are used for EV production, then therapeutically active EVs are obtained, but the finite lifespan of MSCs limits continuous harvesting and scalability
Solution Approach 1:
The patent applies preliminary action by introducing hTERT and cell cycle inhibitor components to MSCs before EV production begins. This genetic modification prepares the cells in advance to overcome their finite lifespan limitation, enabling them to proliferate indefinitely and continuously produce EVs without entering senescence, thus resolving the contradiction between limited cell lifespan and continuous EV harvesting capability
Solution Approach 2:
The patent changes the biological parameters of MSCs by modifying their genetic expression profile through hTERT overexpression and cell cycle regulator inhibition. This parameter change transforms the cells from finite lifespan to immortalized status, allowing sustained proliferation and continuous EV production, thereby resolving the contradiction between cell lifespan duration and productivity
2Duration of action of stationary object
If immortalization methods are applied to extend MSC lifespan, then continuous EV production is enabled, but potential loss of therapeutic properties may occur
Solution Approach 1:
The patent uses cell cycle inhibitors (such as p16, p21, or p53 inhibitors) as intermediaries to achieve immortalization without directly activating oncogenic pathways. These inhibitors mediate the transformation by blocking senescence checkpoints while preserving the differentiated state and secretory function of MSCs, ensuring that EVs maintain their therapeutic properties even as cells become immortalized
Solution Approach 2:
The patent applies local quality by selectively modifying specific cellular functions (proliferation control through hTERT and cell cycle regulation) while leaving other critical functions (differentiation potential and secretome composition) unchanged. This targeted approach ensures that immortalization occurs without compromising the therapeutic quality and immunomodulatory properties of the EVs produced
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method allows for the continuous production of therapeutically active EVs, maintaining their immunomodulatory and regenerative properties, thereby overcoming the limitations of finite MSC lifespan and enabling scalable therapeutic applications.
Implementation Method 1
contacting the target cell with a finite life-span with at least: (a) a human Telomerase reverse transcriptase (hTERT) protein
Implementation Method 2
one or more inhibitors of the expression, function and/or stability of a cell cycle regulator/tumour suppressor protein
Data Source
AI summary
The invention pertains to a method for immortalising cells that are used for the harvesting of extracellular vesicles (EV). EV, derived for example from mesenchymal stromal cells, but also from other cell types, are known to induce beneficial effects during treatment of for example autoimmune disorders. However, the generation of secreting mesenchymal stromal cells is often dependent on donor material or the fact that isolated cells have a limited life span and limited number of passages of cell culture. The present invention provides a method of immortalising such secreting cells, the immortalised cells and medical applications thereof.